New Media Offers Cost-Efficient Ways to Reach and Engage Targets

Manhattan ResearchOver 145 million U.S. adults use the Internet to research health information, according to pharmaceutical and healthcare market research company Manhattan Research. The company has just released Cybercitizen Health v8.0, a multi-client study and strategic advisory service focused on how consumers use media and technology for health information and its impact on treatment and product decisions.

"Tough economic times cause marketers to be held more accountable for spending and measurement," said Mark Bard, Manhattan Research President, "With over 145 million consumers online for health, new media offers cost-effective ways to reach and engage target audiences. In order to efficiently allocate budgets, companies must understand the rapidly evolving health media channels and how consumers are using them to complement and replace the traditional offline health system."

Manhattan Research will host a webinar event, "Is TV Dead? How the New New Media Changes Pharmaceutical DTC Advertising," on October 14th at 11am EST and October 16th at 3pm EST. The webinar will help pharmaceutical and healthcare marketers understand the optimal media mix in the face of an uncertain economy. Meredith Abreu Ressi, VP of Research, will overview key market data and trends from CybercitizenÒ Health v8.0. Register here: https://manhattanresearch.webex.com.

Webinar Topics:

  • Evolving Consumer Use of TV and Video

How can marketers play the consumer shift to online video for entertainment and information to their advantage?

  • Going Mobile for Health

What are the latest trends and strategies for reaching a growing market of consumers using their mobile phones to find health info?

  • Engaging in Health 2.0

How are patients and caregivers using online communities, widgets, blogs, and wikis, and what should companies and agencies be doing about it? This topic is especially relevant for marketers looking to reach those most active in health social media, like cancer and fibromyalgia patients.

  • The Online Health Shake Up

What will the recent Waterfront Media-Revolution Health merger mean for pharma companies and their media partners? How can marketers stay ahead of the curve? Will sites eventually serve as a conduit linking physicians with their patients?

  • The Doctor…err…the Internet will See You Now

How does the decrease in consumer reliance on the physician affect your brand?

About Cybercitizen® Health v8.0
Cybercitizen® Health was fielded in Q3 2008 among 8,714 U.S. adults (ages 18+). In addition to the data, clients receive strategic deliverables including research reports, client briefings, and access to the Manhattan Research analyst team to answer specific questions. For topics and available therapeutic segmentations (80+), visit http://www.manhattanresearch.com/cch.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...

GSK and Vir Biotechnology announce United States g…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase so...

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer and BioNTech receive expanded U.S. FDA emer…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...